Study finds cystic fibrosis drug allows patients to safely scale back lung therapies

A new multi-site study led by researchers at CU Anschutz shows that people with cystic fibrosis (CF) who start the triple-drug therapy elexacaftor/tezacaftor/ivacaftor (ETI) can safely reduce many of their daily lung treatments while maintaining…

Continue Reading

News Source: medicalxpress.com